New EMA conflicts of interests policy could curtail patient expert advice, says EFPIA
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is toughening its conflicts of interests policy to further ensure that its scientific experts do not have links to the pharmaceutical industry that affect their impartiality. However, the industry is concerned that a lack of clarity in the new policy may end up in a shortage of patient experts who are able to "feedback" to either the agency or pharmaceutical companies.